SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending amidst an "unprecedented" memory shortage, fueled by surging AI demand for High-Bandwidth Memory (HBM) that experts project will persist into 2027. The community is highly optimistic, highlighting Micron's unique position as the sole U.S. HBM producer, its relatively low valuation, and recent analyst upgrades. This strong bullish sentiment is reinforced by news of significant manufacturing expansions and a substantial insider share purchase.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is actively trending due to reports of China blocking shipments of its H200 AI chips, coupled with broader market uncertainty from escalating international trade tensions. While some investors anticipate market turbulence, a strong bullish contingent emphasizes NVIDIA's entrenched AI leadership and robust demand for its next-generation Blackwell and Rubin platforms, viewing current dips as prime buying opportunities.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is currently trending due to a sharp price drop and heightened volatility, fueled by recent critical reports and ongoing speculation of market manipulation. Despite the downturn, community discussions highlight conviction in its robust AI-powered ad platform and anticipate a rebound, particularly with upcoming earnings expected to showcase strong fundamentals.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is actively trending amid intense community debate surrounding its tokenomics and upcoming developments. While some express concern over perceived continuous coin minting impacting supply, others are highly optimistic about the proposed 'Mission 70' initiative, designed to significantly reduce inflation. This comes as the community anticipates key Web3 events, positioning ICP as a foundational layer for decentralized cloud and AI applications, with many expecting significant adoption news.

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept Inc

Venus Concept Inc. (VERO) is trending following the disclosure that a single institutional shareholder now controls 91% of the company's shares, creating an extremely tight public float. This has spurred a heated debate among investors, with many anticipating an unprecedented short squeeze and significant price appreciation due to the limited tradable shares. Conversely, a vocal group warns of a potential pump-and-dump, highlighting the company's underlying fundamentals and the risk of delisting at a low valuation.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a top trending stock as investors eagerly await its upcoming earnings report, with community perspectives sharply divided on whether the company will deliver a strong rebound from oversold conditions. A significant talking point revolves around the ongoing Warner Bros. Discovery acquisition saga, with bulls seeing it as a growth catalyst and bears concerned about its financial impact. Recent disclosures regarding bond purchases by a prominent political figure in both Netflix and Warner Bros. Discovery further add to the market's mixed sentiment and speculation surrounding the deal's future.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending intensely following Saudi Arabia's groundbreaking approval of its Anktiva treatment for lung cancer, marking the first global nod for this non-chemo combination, alongside significant progress in its AI-driven NK cell manufacturing. This development, amplified by Dr. Patrick Soon-Shiong's direct public engagement, is fueling widespread community excitement about a potential paradigm shift in oncology and fervent speculation regarding a short squeeze amidst high market interest. Investors and patients alike are discussing the implications of international regulatory confidence and the company's efforts to revolutionize cancer treatment accessibility and cost, putting immense pressure on traditional pharmaceutical and regulatory landscapes.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is actively discussed amidst renewed concerns over potential US tariffs on European economies related to Greenland, which has prompted caution in European markets and the bond sector. This geopolitical tension has sharply divided the community, with many anticipating a significant market pullback, while a strong counter-narrative expects a swift "buy the dip" recovery based on historical resilience to similar events.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors anticipate an upcoming business update call, which follows a major joint venture with a Saudi industrial conglomerate securing 100% offtake for its Greenland rare earth production. The community is buzzing with discussion around Greenland's strategic importance for critical minerals, intensified by geopolitical developments highlighting the need for secure supply chains. This confluence of news positions CRML as a central focus for those seeking exposure to the crucial rare earths sector.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

The United States Natural Gas Fund (UNG) is trending due to forecasts predicting an intense cold snap across large parts of the US, which is expected to significantly boost heating demand. Community sentiment is largely divided between those anticipating a major short squeeze and a sustained rally, possibly fueled by growing energy needs for AI data centers, and those remaining wary of natural gas's notorious volatility and strong production levels that could temper further gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape

Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape PR Newswire VANCOUVER, BC, Jan. 16, 2026 Issued on behalf...

GT Biopharma Submits IND For GTB-5550 TriKE To Treat Solid Tumors

(RTTNews) - GT Biopharma, Inc. (GTBP) on Thursday said it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for GTB-5550 TriKE, designed to target...

EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment

GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026.read more...

Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines

Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines PR Newswire...

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 PR Newswire VANCOUVER, BC, Dec. 19...

Platform Technologies Drive $211B Surge in Precision Cancer Treatment

Platform Technologies Drive $211B Surge in Precision Cancer Treatment Platform Technologies Drive $211B Surge in Precision Cancer Treatment PR Newswire VANCOUVER, BC, Dec. 11, 2025 Issued on behalf...

Stocks & Markets Podcast: Biotech CEO reveals the science of humane cancer treatment

This article is based on TheStreet's Stock & Markets Podcast. Hosted by Chris Versace, the veteran Wall Street investor and lead portfolio manager for TheStreet Pro, the weekly podcasts are available...

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points PR Newswire VANCOUVER, BC, Dec...

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation PR Newswire VANCOUVER, BC, Oct. 17, 2025...

Precision Oncology Approaches Drive $312B Market Transformation

Precision Oncology Approaches Drive $312B Market Transformation Precision Oncology Approaches Drive $312B Market Transformation PR Newswire VANCOUVER, Oct. 17, 2025 USA News Group News Commentary...

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.

GTBP
GT Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GTBP News

GTBPGT Biopharma Inc